GEN Exclusives

More »

GEN News Highlights

More »
Aug 31, 2009

PsychoGenics to Assess AstraZeneca Candidates for Treating Central Nervous System Disorders

  • AstraZeneca signed on PsychoGenics to evaluate a number of its drug candidates for their potential to treat psychiatric disorders. The company will use its high-throughput drug discovery platforms that combine behavioral neurobiology with robotics, bioinformatics, and computer vision.

    PsychoGenics will receive research payments and milestones commensurate with the stage of development. The company is also entitled to royalties on any future sales.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?